Recombinant human vascular endothelial growth factor(rhVEGF165) Product Technical Manual

1. Product Overview

Recombinant human vascular endothelial growth factor（Recombinant Human Vascular Endothelial Growth Factor, rhVEGF）It is a homodimeric glycoprotein belonging to the platelet-derived growth factor (PDGF) family. In the human body, VEGF has multiple subtypes (such as VEGF121, VEGF165, VEGF189, etc.), among whichVEGF165It is a subtype with strong biological activity, abundant expression in tissues, and wide scientific applications.

This product utilizes gene recombination technology（E. coli ）Preparation, obtained through a multi-step chromatography purification process. It can specifically bind to receptors on the surface of vascular endothelial cells and is the most critical regulatory factor in the processes of angiogenesis and vasculogenesis. The rhVEGF we provide has the characteristics of high purity, high specific activity, and low endotoxin, making it an ideal reagent for cell culture, tissue engineering, and drug development.

2. Mechanism of Action

As a potent mitogen, the biological effects of rhVEGF165 are mainly achieved through the following mechanisms:

1. Receptor specific binding:RhVEGF165 can bind with high affinity to two tyrosine kinase receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). Among them, VEGFR-2 is the main receptor that mediates endothelial cell proliferation and angiogenesis signaling.

2. Signal pathway activation:After binding to the receptor, it induces receptor dimerization and self phosphorylation, activating downstream signaling pathways such as PLC γ - PKC-MAPK.

3. Biological function execution:

• Promote proliferation and migration:Significantly promote the division and proliferation of vascular endothelial cells, and induce their migration towards angiogenic regions.

• Increase vascular permeability:It is one of the known vascular permeability inducers, which helps with plasma protein extravasation and builds a matrix for neovascularization.

• Anti apoptotic effect:Inducing the expression of anti apoptotic proteins (such as Bcl-2) to maintain the survival of the neovascularization network.

3. Key Features of the Product

• Biological activity:Each batch of products has been validated through human umbilical vein endothelial cell (HUVEC) proliferation experiments. ED50 is usually within the range of 1-5 ng/mL, with a specific activity of ≥ 2.0 × 10 ^ 5 IU/mg, ensuring high sensitivity of experimental data.

• High purity level:According to SDS-PAGE electrophoresis detection, the purity is>95% (even up to 98%), greatly reducing the interference of impurities on sensitive cell experiments.

• Extremely low endotoxin levels:Adopting the endotoxin removal process, the endotoxin level is less than 0.1 EU/μ g (LAL method), meeting the stringent requirements of stem cell induction, organoid culture, and in vivo injection experiments.

• Batch stability:Strictly follow the quality management system and control the Lot to Lot Variation within 5% to ensure the consistency of your long-term experimental data.

4. Wide range of applications

A. Basic Cell Biology Research

• Endothelial cell culture:As an essential additive in serum-free culture medium for HUVEC or other vascular endothelial cells, it maintains cell state and proliferation.

• Angiogenesis model:Used for in vitro "Tube Formation Assay" or in vivo "Chicken Embryo Choriobladder Membrane (CAM) Experiment" to study the molecular mechanism of angiogenesis.

B. Stem cells and regenerative medicine

• Targeted induction of differentiation:Inducing differentiation of embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) into the endothelial cell lineage.

• Organizational Engineering:When constructing artificial skin, bone repair materials, or myocardial patches, adding rhVEGF can promote the construction of vascular networks within the graft and solve the "blood supply bottleneck" problem in tissue engineering.

C. Organoids construction

• VEGF is a key factor in constructing vascularized organs in the culture system of kidney like organs, liver like organs, or tumor like organs, which helps simulate a more realistic in vivo microenvironment.

D. Drug screening and tumor research

• Target research:Tumor cells often overexpress VEGF to obtain nutrients. RhVEGF can serve as a positive control for screening anti angiogenic drugs (such as bevacizumab analogs) or studying the tumor microenvironment.